Nathaniel Weygant

2.1k total citations
55 papers, 1.5k citations indexed

About

Nathaniel Weygant is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Nathaniel Weygant has authored 55 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 19 papers in Molecular Biology and 12 papers in Cancer Research. Recurrent topics in Nathaniel Weygant's work include Cancer Cells and Metastasis (25 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Cancer Genomics and Diagnostics (7 papers). Nathaniel Weygant is often cited by papers focused on Cancer Cells and Metastasis (25 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Cancer Genomics and Diagnostics (7 papers). Nathaniel Weygant collaborates with scholars based in United States, China and Germany. Nathaniel Weygant's co-authors include Dongfeng Qu, Courtney W. Houchen, Parthasarathy Chandrakesan, Randal May, Sripathi M. Sureban, Naushad Ali, William L. Berry, Stan Lightfoot, Michael S. Bronze and Jun Peng and has published in prestigious journals such as Gastroenterology, PLoS ONE and Cancer Research.

In The Last Decade

Nathaniel Weygant

54 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathaniel Weygant United States 26 753 651 358 301 214 55 1.5k
Julie Pannequin France 21 590 0.8× 945 1.5× 344 1.0× 167 0.6× 120 0.6× 46 1.7k
Lionel Larribère Germany 23 548 0.7× 893 1.4× 221 0.6× 426 1.4× 292 1.4× 42 1.6k
Hideyuki Komekado Japan 15 441 0.6× 737 1.1× 157 0.4× 172 0.6× 267 1.2× 30 1.4k
Chanel E. Smart Australia 19 433 0.6× 988 1.5× 576 1.6× 116 0.4× 118 0.6× 40 1.5k
Julio C. Tapia Chile 24 309 0.4× 1.1k 1.7× 282 0.8× 296 1.0× 115 0.5× 60 1.6k
Takatsune Shimizu Japan 20 416 0.6× 763 1.2× 259 0.7× 197 0.7× 302 1.4× 42 1.5k
Esra Erdal Türkiye 22 345 0.5× 825 1.3× 316 0.9× 171 0.6× 100 0.5× 43 1.5k
Catherine Gratas France 21 361 0.5× 1.1k 1.6× 394 1.1× 119 0.4× 254 1.2× 38 1.7k
Yoshikazu Johmura Japan 20 310 0.4× 1.3k 2.0× 180 0.5× 338 1.1× 236 1.1× 47 1.9k
Sylvia Kaden Germany 16 319 0.4× 755 1.2× 173 0.5× 129 0.4× 379 1.8× 23 1.6k

Countries citing papers authored by Nathaniel Weygant

Since Specialization
Citations

This map shows the geographic impact of Nathaniel Weygant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathaniel Weygant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathaniel Weygant more than expected).

Fields of papers citing papers by Nathaniel Weygant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathaniel Weygant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathaniel Weygant. The network helps show where Nathaniel Weygant may publish in the future.

Co-authorship network of co-authors of Nathaniel Weygant

This figure shows the co-authorship network connecting the top 25 collaborators of Nathaniel Weygant. A scholar is included among the top collaborators of Nathaniel Weygant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathaniel Weygant. Nathaniel Weygant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weygant, Nathaniel, et al.. (2025). Triptolide targets PPP2CA/ITGA5 axis to suppress lactate-driven ovarian cancer progression. Chinese Medicine. 20(1). 122–122.
2.
Wen, Jie, Fangkun Liu, Quan Cheng, et al.. (2023). Applications of organoid technology to brain tumors. CNS Neuroscience & Therapeutics. 29(10). 2725–2743. 23 indexed citations
3.
Weygant, Nathaniel, et al.. (2023). DCLK1 and tuft cells: Immune-related functions and implications for cancer immunotherapy. Critical Reviews in Oncology/Hematology. 191. 104118–104118. 3 indexed citations
4.
Duan, Ling, et al.. (2022). Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma. Technology in Cancer Research & Treatment. 21. 4 indexed citations
5.
Cao, Zhiyun, et al.. (2022). Emerging Prospects for the Study of Colorectal Cancer Stem Cells usingPatient-derived Organoids. Current Cancer Drug Targets. 22(3). 195–208. 4 indexed citations
6.
Feng, Hailan, et al.. (2022). Role of DCLK1 in oncogenic signaling (Review). International Journal of Oncology. 61(5). 9 indexed citations
7.
Ge, Yang, Huiyun Zhang, Nathaniel Weygant, & Jiannan Yao. (2021). Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Frontiers in Pharmacology. 12. 640099–640099. 2 indexed citations
8.
Chandrakesan, Parthasarathy, Janani Panneerselvam, Randal May, et al.. (2020). DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular Cancer Therapeutics. 19(7). 1539–1549. 27 indexed citations
9.
Cao, Zhiyun, Nathaniel Weygant, Parthasarathy Chandrakesan, et al.. (2020). Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. Cancers. 12(12). 3801–3801. 36 indexed citations
10.
Nofchissey, Robert A., Maaz Khan, Megan R. Lerner, et al.. (2020). The role of sex in the innate and adaptive immune environment of metastatic colorectal cancer. British Journal of Cancer. 123(4). 624–632. 22 indexed citations
11.
Shen, Zhiqing, Xiangyan Wu, Jianfeng Chu, et al.. (2020). Huoxin pill attenuates myocardial infarction-induced apoptosis and fibrosis via suppression of p53 and TGF-β1/Smad2/3 pathways. Biomedicine & Pharmacotherapy. 130. 110618–110618. 18 indexed citations
12.
Qu, Dongfeng, Nathaniel Weygant, Jiannan Yao, et al.. (2019). Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer. Journal of Oncology. 2019. 1–11. 34 indexed citations
13.
Ge, Yang, Nathaniel Weygant, Dongfeng Qu, et al.. (2018). Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. International Journal of Cancer. 143(5). 1162–1175. 55 indexed citations
14.
Weygant, Nathaniel, Yang Ge, Dongfeng Qu, et al.. (2016). Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem–like Cells Marked by DCLK1 Kinase. Cancer Research. 76(14). 4090–4099. 28 indexed citations
15.
Qu, Dongfeng, Nathaniel Weygant, Randal May, et al.. (2016). Abstract 1731: Overexpression of DCLK1 in pancreatic cancer activates KRAS/PI3K/MTOR pathway signaling and supports tumorigenesis, invasiveness, and stemness. Cancer Research. 76(14_Supplement). 1731–1731. 1 indexed citations
16.
Weygant, Nathaniel, Kenneth J. Vega, & Courtney W. Houchen. (2015). High Tumor DCLK1 Levels at Colorectal Cancer Diagnosis Predict Poor Survival. The American Journal of Gastroenterology. 110. S550–S551. 1 indexed citations
17.
Qu, Dongfeng, Nathaniel Weygant, Randal May, et al.. (2015). Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis. PLoS ONE. 10(8). e0134212–e0134212. 56 indexed citations
18.
Sureban, Sripathi M., Randal May, Nathaniel Weygant, et al.. (2014). XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Letters. 351(1). 151–161. 103 indexed citations
19.
Weygant, Nathaniel, Dongfeng Qu, William L. Berry, et al.. (2014). Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Molecular Cancer. 13(1). 103–103. 92 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Pannequin Breakdown of academic impact, for papers by Lionel Larribère Breakdown of academic impact, for papers by Hideyuki Komekado Breakdown of academic impact, for papers by Chanel E. Smart Breakdown of academic impact, for papers by Julio C. Tapia Breakdown of academic impact, for papers by Takatsune Shimizu Breakdown of academic impact, for papers by Esra Erdal Breakdown of academic impact, for papers by Catherine Gratas Breakdown of academic impact, for papers by Yoshikazu Johmura Breakdown of academic impact, for papers by Sylvia Kaden
Rankless by CCL
2026